All GLG News Analyses Filed Under: Endocrinology
Posted June 9, 2008
Tight Rein on Blood Sugar Has No Heart Benefit
Analysis of: Tight Rein on Blood Sugar Has No Heart Benefit | www.nytimes.com
Author: GLG Member Program Contributor
Analysis of: Tight Rein on Blood Sugar Has No Heart Benefit | www.nytimes.com
Author: GLG Member Program Contributor
The article did not focus on insulin. This is the hormonoal bad guy. Numerous studies looking at sulfonoureas vs glucophage, alpha-glucosidase inhibitors (Acarbose, etc) clearly demonstrate this. If you want real insight into the failures of this study and why, talk with me. Thomas...
Posted June 9, 2008
Tight Rein on Blood Sugar Has No Heart Benefit
Analysis of: Tight Rein on Blood Sugar Has No Heart Benefit | www.nytimes.com
Author: GLG Member Program Contributor
Analysis of: Tight Rein on Blood Sugar Has No Heart Benefit | www.nytimes.com
Author: GLG Member Program Contributor
For years pharmacotherapy had been the mainstay of aggressive diabetic control. With the focus on comprehensive disease management there has been a failure to recognize that blood sugar control alone is actually quite dangerous. Many of the therapies are potentially toxic with significant...
Posted June 9, 2008Diabetes: Let's avoid pseudoscience and start over.....
Analysis of: Tight Rein on Blood Sugar Has No Heart Benefit | www.nytimes.com
Author: Kenneth Algazy, Clinical Professor of Medicine University of Pennsylvania School of Medicine - CC
Tight Glucose control in type 2 diabetes mellitus did not result in improved survival and possibly had a negative impact.
Posted June 9, 2008
Tight Rein on Blood Sugar Has No Heart Benefit
Analysis of: Tight Rein on Blood Sugar Has No Heart Benefit | www.nytimes.com
Author: GLG Member Program Contributor
Analysis of: Tight Rein on Blood Sugar Has No Heart Benefit | www.nytimes.com
Author: GLG Member Program Contributor
Two studies (ACCORD and ADVANCE) designed to confirm positive effect of tight blood sugar control on the rate of cardiovascular and cerebrovascular events failed to do so. Incidence of hypoglycemia, weight gain and fluid retention, however, was significantly higher in ACCORD trial. Almost half...
Posted June 9, 2008
Tight Rein on Blood Sugar Has No Heart Benefit
Analysis of: Tight Rein on Blood Sugar Has No Heart Benefit | www.nytimes.com
Author: GLG Member Program Contributor
Analysis of: Tight Rein on Blood Sugar Has No Heart Benefit | www.nytimes.com
Author: GLG Member Program Contributor
The whole idea that intensive blood glucose control in type 2 diabetes might reduce heart disease was due to a major misunderstanding of disease pathogenesis and confusion with type 1 diabetes None of the many previous studies of intensive control in type 2 diabetes supported a significant impact on...
Posted May 30, 2008
AtheroGenics Announces Encouraging Interim Results From Phase 3 Clinical Trial of AGI-1067 in Type 2 Diabetes
Analysis of: AtheroGenics Announces Encouraging Interim Results From Phase 3 Clinical Trial of AGI-1067 in Type 2 Diabetes | www.fiercebiotech.com
Author: GLG Member Program Contributor
Analysis of: AtheroGenics Announces Encouraging Interim Results From Phase 3 Clinical Trial of AGI-1067 in Type 2 Diabetes | www.fiercebiotech.com
Author: GLG Member Program Contributor
This compound may have additiional benefit in type 2 diabetic patients, especially those with the cardiometabolic syndrome.
Posted May 14, 2008
DXA Reimbursement Reductions: Implications for Quality Osteoporosis Care, Marjorie Luckey, MD and Roberta Biegel (Washington, DC: National Osteoporosis Foundation, Winter 2005)
Analysis of: DXA Reimbursement Reductions: Implications for Quality Osteoporosis Care, Marjorie Luckey, MD and Roberta Biegel (Washington, DC: National Osteoporosis Foundation, Winter 2005) | osteoporosisblogger.com
Author: GLG Member Program Contributor
Analysis of: DXA Reimbursement Reductions: Implications for Quality Osteoporosis Care, Marjorie Luckey, MD and Roberta Biegel (Washington, DC: National Osteoporosis Foundation, Winter 2005) | osteoporosisblogger.com
Author: GLG Member Program Contributor
key implications: Less reimbursements for DEXA may lead to less testing, as cost of leasing equipment will be greater then revenue derived form procedures However, Less revenue/procedure could lead to greater utilization of equipment to cover costs involved and result in earlier testing of women...
Posted May 12, 2008
Aradigm Announces Data Showing No Occurrence of Primary Lung Cancer in Patients Treated with AERx Insulin Diabetes Management System (iDMS)
Analysis of: Aradigm Announces Data Showing No Occurrence of Primary Lung Cancer in Patients Treated with AERx Insulin Diabetes Management System (iDMS) | pharmalive.com
Author: GLG Member Program Contributor
Analysis of: Aradigm Announces Data Showing No Occurrence of Primary Lung Cancer in Patients Treated with AERx Insulin Diabetes Management System (iDMS) | pharmalive.com
Author: GLG Member Program Contributor
THE IMPLICATIONS HAVE TO DO WITH THE AVAILABILITY OF A PRODUCT THAT BRIDGES THE GAP OF INSULIN THERAPY IN THOSE THAT REQUIRE IT AND STILL WILL NOT USE INJECTABLE INSULIN.
Posted May 6, 2008
Government Cuts in Funding for DXA in Physicians' Offices May Lead to Difficulties for Rural Patients
Analysis of: DXA Reimbursement Reductions: Implications for Quality Osteoporosis Care, Marjorie Luckey, MD and Roberta Biegel (Washington, DC: National Osteoporosis Foundation, Winter 2005) | osteoporosisblogger.com
Author: William Fink, President Managed Care Pharmacy Consultants, Inc
Government Cuts in Funding for DXA in Physicians' Offices May Lead to Difficulties for Rural Patients
Analysis of: DXA Reimbursement Reductions: Implications for Quality Osteoporosis Care, Marjorie Luckey, MD and Roberta Biegel (Washington, DC: National Osteoporosis Foundation, Winter 2005) | osteoporosisblogger.com
Author: William Fink, President Managed Care Pharmacy Consultants, Inc
It is well known that millions of people in the US suffer from osteoporosis which leads directly to debilitating fractures. Early diagnosis of osteoporosis and low bone mass will help prevent chronic pain and loss of independence. Once diagnosed, treatment is readily available and...
Posted April 21, 2008
Study Shows Once-yearly Aclasta Better Than Risedronate at Increasing Bone Mass in Patients with Osteoporosis Caused by Glucocorticoids
Analysis of: Study Shows Once-yearly Aclasta Better Than Risedronate at Increasing Bone Mass in Patients with Osteoporosis Caused by Glucocorticoids | pharmalive.com
Author: GLG Member Program Contributor
Previous
Page :
1 2 3 4 5 6 7 8 9 10 11 12 Next21 to
30
of 341Analysis of: Study Shows Once-yearly Aclasta Better Than Risedronate at Increasing Bone Mass in Patients with Osteoporosis Caused by Glucocorticoids | pharmalive.com
Author: GLG Member Program Contributor
Osteoporosis is a major issue in the aging population. Fractures of the hip and spine can be catastrophic occurrences for the elderly as even with surgical and image guided treatment, the ensuing morbidity can alter a patients life style. Reducing osteoporosis can reduce medical costs but preventing...
More GLG News in
Healthcare
Most Popular:
Source Article | Expert Analyses
FDA Approves EVOLENCE®, a New Generation Collagen-Based Facial Filler
www.investor.jnj.com
Longer Lashes in a Tube? Maybe Not
www.nytimes.com
Medicare fees to doctors fall Tuesday
news.yahoo.com
Doctors Say Medication Is Overused in Dementia
www.nytimes.com
Why anaesthetics can make the pain worse
www.newscientist.com
An illegal use of Lumigan, now legal?
July 3, 2008
How are we to pay for computers with a 10% drop in Medicare fees?
June 30, 2008
Obesity: Higher Healthcare Costs, Lower Productivity
June 26, 2008
Best acne care product I've seen.
June 25, 2008
Jeff is in accounting not a healthcare provider.
June 23, 2008

